Dublin, April 23, 2020 (GLOBE NEWSWIRE) -- The "Continuous Glucose Monitoring: The Current State of the Art" report has been added to ResearchAndMarkets.com's offering.

The scope of this study includes what a CGM is, how it works and how a PWD wears the device. This study also includes advances in the technology - both those advances being seen in the market today and advances for which CE mark or FDA approval is pending. There is a section covering the pancreas and diabetes, including the continued growth in the number of diabetics and prediabetics in the U.S. and elsewhere. It covers selected clinical trials pertaining to the evolution and proliferation of CGMs. The scope of this report includes novel CGMs and components in development. These may or may not ever see a market launch but should nonetheless be of interest to industry managers.

Also covered here are selected regulatory and reimbursement affairs. Regulatory guidelines need to keep abreast of the technological developments so that safe, effective devices may enter the market. Without sufficient, carefully crafted reimbursement or payer coverage, the devices will never get off the ground. Both favorable regulatory and reimbursement guidelines are needed if manufacturers are to continue to develop and commercialize the best equipment for managing diabetes.

Selected companies are profiled in this report. These include not only the market leaders - Dexcom, Medtronic, Abbott, Tandem, and Insulet - but also smaller companies working on promising technology.

Not covered in the scope of this report is an in-depth analysis of market values and growth rates. These are available in other reports by the publisher. Also not covered is the ultimate in the artificial pancreas: the cell-based implant. While these are under development, for practical purposes implants seem to be some distance down the road.

The Report Includes:

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Definitions

4 Increasing Patient Choice and Device Interoperability

5 Novel CGMs and Components in Development

6 Technological Promises or Hype?

7 Selected Regulatory and Reimbursement Affairs

8 Selected Clinical Trials

9 Company Profiles

10 Appendix: Terms and Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/fvsxp

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. 

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900